Abstract 5142
Background
Thermal Liquid Biopsy (TLB) is based on Differential Scanning Calorimetry (DSC, calorimetric thermogram analysis of serum samples) as a new clinical approach for diagnostic assessment of lung cancer patients. DSC is highly sensitive and it studies the unfolding transitions in proteins by thermal denaturation. The DSC profile of blood serum has been previously proposed as a novel approach for diagnosis and monitoring several diseases. Our main objective is to determine the TLB capacity to differentiate between Healthy Controls (HC) and Lung Cancer Patients (LCP).
Methods
Blood samples from HC and LCP were analyzed with a high sensitivity microcalorimeter VP-DSC (MicroCal-Malvern). The data were processed by Origin 7 software. Thermograms acquired were analyzed with a multiparametric method developed by our research group, procuring some indicators to interpret the results. The Area Under the Curve (AUC) was analyzed and the Youden’s Index obtained from ROC curves, allowing to construct the contingency tables. Odds Ratio (OR) was also calculated by binary logistic regression.
Results
117 samples from LCP (Average age 64.6±8.7, 83.0% men) stage distribution (II: 5.2%, III: 25.9%; IV: 69.0%), smoking status (63.8% smoking, 6.5% non-smoking) histology distribution (37.1% Adenocarcinoma, 28.4% Squamous, 30.2% small cell) compared to 123 HC from a blood bank with homogeneous distribution. 10 out of 28 parameters of our multiparametric method showed statistical differences between HC and LCP. After developing ROC curves, AUC higher than 0.75 were observed in these 10 parameters, exceeding 0.85 in 3 of them. The Youden’s index was calculated for all, finding sensitivity and specificity values higher than 75.0-90.0% (for the best parameter both were more than 85.0%). Comparing HC to LCP, we calculated OR obtaining 10 parameters over 10, showing a high positive association between clinical parameters and DSC results.
Conclusions
High positive association between clinical groups and TLB parameters offers advantages over current diagnosis techniques (CT imaging), providing a powerful diagnostic approach with a minimally-invasive, low-risk, low-cost clinical test for LCP. Future promising applications, such as screening programs, could be developed from TLB.
Clinical trial identification
Legal entity responsible for the study
Instituto Investigación Sanitaria de Aragón (ISS).
Funding
Institute Carlos III (Spain).
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract